

Notes

**Thyroxine Analogs. XVII.¹ 3,5-Di(ethylthio)-
and 3,5-Di(phenylthio)-DL-thyronines
and Their 3'-Isopropyl Analogs**

EUGENE C. JORGENSEN, RICHARD O. MUHLHAUSER,
AND ROBERT A. WILEY

Department of Pharmaceutical Chemistry, School of Pharmacy,
University of California, San Francisco Medical Center,
San Francisco, California 94122

Received March 11, 1969

A wide variety of groups have replaced the 3'-iodine atom of 3,5,3'-triiodo-L-thyronine with retention of thyroid hormonal activity.² However, requirements for the 3,5-iodine atoms have been more restrictive, only bromine^{1,3} or methyl⁴ substitution leading to active analogs among the limited series studied.⁵ The synthesis of analogs containing 3,5-di(ethylthio) and 3,5-di(phenylthio) substituents on the thyronine nucleus was undertaken to provide additional data on substituent requirements for the alanine-bearing ring, and in an attempt to prepare a halogen-free thyromimetic compound.

A positive correlation has been noted between thyroxine-like effects in rodents, and lipophilic and electronic character of the 3'- and 5'-halogen substituents of thyroxine analogs.⁶ A similar relationship has been reported for the alkyl, aryl, and halogen substituents in the 3' position of 3,5-diiodothyronines.⁷ Activity rises to a maximum with increasing lipophilic character, as measured by the Hansch substituent constant, π .⁸ Activity is further enhanced by electron-donating groups, as measured by the Hammett σ_p value.⁹ Thus, 3,5-diiodo-3'-isopropyl-L-thyronine ($\pi_{i-Pr} = 1.30$; $\sigma_{i-Pr} = -0.15$) is 700–1200% as active as L-thyroxine, the isopropyl group currently being the most effective 3' substituent.^{2c} The activities of

compounds containing substituents other than iodine in the 3,5 positions, such as 3,5-dibromo-3'-isopropyl-L-thyronine¹⁰ (170% of L-thyroxine; $\pi_{Br} = 0.94$; $\sigma_{Br} = 0.23$) and 3,5-dimethyl-3'-iodo-DL-thyronine⁴ (3% of L-thyroxine; $\pi_{Me} = 0.51$, $\sigma_{Me} = -0.17$), indicated that such a correlation might be extended to substituents in the 3,5 positions. The ethylthio group (C_2H_5S) has a lipophilic character ($\pi_{C_2H_5S} = 1.13$)¹¹ close to that of iodine ($\pi_I = 1.15$),⁶ and an electronic character ($\sigma_{C_2H_5S} = 0.03$) between that of groups which confer activity in the 3,5 positions, iodine ($\sigma_I = 0.28$) and methyl ($\sigma_{CH_3} = -0.17$). The phenylthio group was selected as representative of a highly lipophilic ($\pi_{C_6H_5S} = 2.0$)¹² substituent. In both the ethylthio and phenylthio series, analogs containing the biologically activating 3'-isopropyl substituent were included.

N-Acetyl-3,5-diiodo-L-tyrosine ethyl ester (**1**) was converted into its 3,5-di(ethylthio) derivative (**2**) by reaction with cuprous ethyl mercaptide (see Scheme I). However, **2** did not react with di(*p*-anisyl)iodonium bromide (**3a**) in the presence of Cu powder and NEt_3 ^{13,14} or KO-*t*-Bu in *t*-BuOH.⁴ Therefore, the intermediate diiododiphenyl ethers (**4a**, **4b**) were formed by reaction of **1** with the diaryliodonium salts (**3a**, **3b**). The intermediate **4b** was identical with a sample prepared by a longer route,¹⁵ which established the position of the 3'-isopropyl group. Reaction of **4a** and **4b** with cuprous ethyl mercaptide yielded the ethylthio ethers (**5a**, **5b**), and with cuprous phenyl mercaptide, the phenylthio ethers (**8a**, **8b**) by methods developed by Adams, *et al.*¹⁶ Reactions carried out under N_2 resulted in purer products in higher yield than those reactions carried out in the absence of nitrogen. Relative to the nmr spectra of the 3,5-diiododiphenyl ethers¹⁷ (**4a**, **4b**), 3,5-di(phenylthio) substitution (**8a**, **8b**) produced an upfield shift of about 0.22 ppm for the 2,6-protons and for protons in the N-acetylalanine ethyl ester side chain. Ethylthio substitution (**5a**, **5b**) did not produce this effect, which must have been due to the positioning of the 2,6- and side-chain protons above or below the planes of the phenylthio groups.¹⁷

Hydrolysis of **8a** and **8b** with HBr yielded the phenylthio-substituted amino acids (**9a**, **9b**). However, treatment of **5b** under these conditions caused partial loss of the ethylthio group,¹⁸ under conditions which

(1) Paper XVI: E. C. Jorgensen and J. R. Nulu, *J. Pharm. Sci.*, in press. This investigation was supported by Research Grant AM-04223 from the National Institute of Arthritis and Metabolic Diseases, U. S. Public Health Service.

(2) (a) N. Zenker and E. C. Jorgensen, *J. Amer. Chem. Soc.*, **81**, 4643 (1959); (b) E. C. Jorgensen, P. A. Lehman, C. Greenberg, and N. Zenker, *J. Biol. Chem.*, **237**, 3832 (1962); (c) C. M. Greenberg, B. Blank, F. R. Pfeiffer, and J. F. Pauls, *Am. J. Physiol.*, **201**, 732 (1961); (d) E. C. Jorgensen and J. A. W. Reid, *J. Med. Chem.*, **8**, 533 (1965); (e) S. B. Barker, M. Shimada, and M. Makiuchi, *Endocrinology*, **76**, 115 (1965); (f) M. Wool, V. S. Fang, and H. A. Selenkow, *ibid.*, **78**, 29 (1966).

(3) M. V. Mussett and R. Pitt-Rivers, *Metabolism*, **6**, 18 (1957).

(4) E. C. Jorgensen and R. A. Wiley, *J. Med. Pharm. Chem.*, **5**, 1307 (1962).

(5) (a) H. J. Bielig and G. Lützel, *Ann. Chem.*, **608**, 140 (1957); (b) E. C. Jorgensen and R. A. Wiley, *J. Med. Chem.*, **6**, 459 (1963); (c) T. Matsuura, T. Nagamichi, K. Matsuo, and A. Nishinaga, *ibid.*, **11**, 899 (1968).

(6) (a) C. Hansch and T. Fujita, *J. Amer. Chem. Soc.*, **86**, 1616 (1964); (b) C. Hansch, A. R. Steward, J. Iwasa, and E. W. Deutsch, *Mol. Pharmacol.*, **1**, 205 (1965).

(7) E. C. Jorgensen in "Medicinal Chemistry," A. Burger, Ed., 3rd ed, John Wiley and Sons, Inc., New York, N. Y., Chapter 31, in press.

(8) T. Fujita, J. Iwasa, and C. Hansch, *J. Amer. Chem. Soc.*, **86**, 5175 (1964).

(9) D. A. McDaniel and H. C. Brown, *J. Org. Chem.*, **23**, 420 (1958).

(10) R. E. Taylor, Jr., T. Tu, S. B. Barker, and E. C. Jorgensen, *Endocrinology*, **80**, 1143 (1967).

(11) Estimated^{6,8} by $\pi_{SCH_3}(0.62) + \pi_{CH_3}(0.51)$.

(12) Estimated^{6,8} by $\pi_{C_6H_5}(1.89) + \pi_{SCH_3}(0.62) - \pi_{CH_3}(0.51)$.

(13) (a) G. Hillmann, *Z. Naturforsch.*, **116**, 419 (1956); (b) G. Hillmann, U. S. Patent 2,886,592 (May 12, 1959).

(14) P. F. Bevilacqua, J. T. Plati, and W. Wenner, U. S. Patent 2,895,927 (July 21, 1959).


(15) B. Blank, F. R. Pfeiffer, C. M. Greenberg, and J. F. Kerwin, *J. Med. Chem.*, **6**, 554 (1963).

(16) (a) R. Adams, W. Reifschneider, and W. D. Nair, *Croat. Chem. Acta*, **29**, 277 (1957); (b) R. Adams and A. Ferretti, *J. Amer. Chem. Soc.*, **81**, 4927 (1959).

(17) P. A. Lehman and E. C. Jorgensen, *Tetrahedron*, **21**, 363 (1965).

(18) (a) C. M. Suter and J. P. McKenzie, *J. Amer. Chem. Soc.*, **56**, 2407 (1934); (b) C. M. Suter and H. L. Hansen, *ibid.*, **54**, 4100 (1932).

SCHEME I



were necessary for complete hydrolysis of the 4'-methoxy group. 3,5-Di(ethylthio)-3'-isopropyl-L-thyronine was obtained as a mixture of two amino acids which was submitted as such to biological evaluation. Since the 4'-methoxy derivatives of active thyroxine analogs are themselves highly active, **5b** was hydrolyzed with HCl to yield the 3,5-di(ethylthio)-3'-isopropyl-4'-methoxy-L-thyronine (**7**). The less sterically hindered 3,5-di(ethylthio)-L-thyronine (**6a**) was obtained by HBr hydrolysis of **5a**.

Pharmacology.¹⁹—Compounds **6a**, **6b**, **7**, **9a**, and **9b** were inactive when tested for thyroxine-like activity by the rat antigoiter method¹⁹ at dosage levels on a molar basis 100 times that of an effective dose of L-thyronine (3 μg of sodium L-thyronine pentahydrate/100 g of body weight). Compounds **6a**, **9a**, and **9b** were inactive as thyroxine antagonists^{2b} when administered in 100-fold excess together with L-thyronine (3 μg) to thiouracil-fed rats.

These results indicate that the balance of lipophilic and electronic properties correlated with activity of a substituent in the 3' position of the thyroxine nucleus may not be extended to the corresponding 3,5 positions.

(19) E. C. Jorgensen and P. Slade, *J. Med. Pharm. Chem.*, **5**, 729 (1962). Detailed biological results have been submitted and are on file in the office of the American Chemical Society.

However, the effects produced by the thio ether substituents of the present study have not been investigated in the 3' position, and it is possible that these groups are too labile under biological conditions to survive long enough to exert their effects. The susceptibility of alkylthio and arylthio substituents to metabolic oxidation to the more polar sulfoxides and sulfones is well known.²⁰

Experimental Section²¹

N-Acetyl-3,5-di(ethylthio)-L-thyronine Ethyl Ester (2).—A mixture of N-acetyl-3,5-diiodo-L-thyronine ethyl ester²² (1, 5.0 g,

(20) R. T. Williams, "Detoxication Mechanisms," 2nd ed, John Wiley and Sons, Inc., New York, N. Y., 1959.

(21) Melting points were determined with a Thomas-Hoover capillary melting point apparatus and are uncorrected. Microanalyses were performed by the Microanalytical Laboratory, University of California, Berkeley, Calif. Nmr spectra were obtained in CDCl_3 on a Varian A-60 (Me₄Si). The (BAW) is $\text{BuOH-HOAc-H}_2\text{O}$ 10:3:1 solvent system. Ir spectra were obtained with a Beckman IR-8 instrument. Where analyses are indicated only by symbols of the elements, analytical results obtained for those elements were within $\pm 0.4\%$ of the theoretical values. The absence of I₂ in compounds was determined by the sensitive test of heating a sample with concentrated H_2SO_4 over an open flame, and noting the absence of purple vapors. Nmr and ir spectra were consistent for all structures assigned. Compounds named as thyroxine derivatives in the text, are named as in *Chemical Abstracts* in the Experimental Section.

(22) J. H. Barnes, E. T. Borrowes, J. Elks, B. A. Hems, and A. G. Long, *J. Chem. Soc.*, 2824 (1949).

10 mmoles), cuprous ethyl mercaptide^{16b} (3.8 g, 30 mmoles), quinoline (10 ml), and pyridine (0.5 ml) was stirred and heated under N₂ at a bath temperature of 175–178° for 3 hr. The black reaction mixture was poured onto a mixture of concentrated HCl (40 ml) and ice (200 g) and allowed to stand overnight. The solid was removed by filtration and extracted with three 100-ml portions of Et₂O and four 100-ml portions of EtOAc. The combined Et₂O and EtOAc extracts were washed with 5% HCl and with H₂O, dried (Na₂SO₄), and evaporated to yield 1.45 g of a brown solid. Crystallization from EtOH gave 0.89 g (22%) of **2** as yellow-white crystals, mp 103–103.5°, iodine absent. *Anal.* (C₁₇H₂₃NO₄S₂) C, H, S.

No formation of **5a** was detected by the attempted condensation of **2** with di(*p*-anisyl)iodonium bromide (**3a**) in the presence of Cu powder and Et₃N,^{13,14} or KO-*t*-Bu in *t*-BuOH.⁴

N-Acetyl-3,5-diiodo-4-(3'-isopropyl-4'-methoxyphenoxy)phenyl-L-alanine Ethyl Ester (4b).—N-Acetyl-3,5-diiodo-L-tyrosine ethyl ester²² (2.6 g, 5.2 mmoles), di(3-isopropyl-4-methoxyphenyl)iodonium iodide²³ (5.15 g, 9.3 mmoles), powdered Cu (45 mg), MeOH (62 ml), and Et₃N (0.77 ml) were stirred at room temperature for 24 hr. Additional MeOH (50 ml), Et₃N (0.8 ml), and Cu (45 mg) were added and stirring was continued for 24 hr. After filtration, the solvent was evaporated, and the residue was taken up in C₆H₆ (70 ml) and 3% HCl (50 ml) and shaken for 5 min. The precipitated Et₃N·HCl was removed by filtration, the C₆H₆ solution was washed (H₂O, 1 N NaOH, H₂O) and dried (Na₂SO₄), and the C₆H₆ was removed *in vacuo*. The addition of petroleum ether (bp 30–60°) (density, 0.67–0.69) gave a white solid, mp 129–131°. Crystallization from H₂O–EtOH yielded 1.2 g (36%); mp 129–131°, lit.¹⁵ mp 129–131°; tlc (EtOAc), one spot, R_f 0.75; nmr and ir spectra were identical with a sample prepared by the method of Blank.¹⁵ *Anal.* (C₂₃H₂₇I₂NO₅) C, H, I.

N-Acetyl-3,5-di(ethylthio)-4-(3'-isopropyl-4'-methoxyphenoxy)phenyl-L-alanine Ethyl Ester (5b).—N₂ was passed through a stirred mixture of **4b** (3.2 g, 4.9 mmoles), cuprous ethyl mercaptide^{16b} (3.25 g, 26.1 mmoles), quinoline (8.2 ml), and pyridine (0.41 ml), heated in a bath at 160–190° for 3.5 hr. The reaction mixture was poured onto HCl (40 ml) and ice (300 g) and allowed to stand overnight. The precipitated solid was removed by filtration and extracted with Et₂O (1 l.). The Et₂O solution was washed with 5% HCl (750 ml) and H₂O (800 ml), dried (Na₂SO₄), and evaporated to give 2.4 g of oily solid which was dissolved in C₆H₆ and chromatographed on acid-washed alumina (30 g). Elution with C₆H₆ and 20% CHCl₃–C₆H₆ and evaporation of the combined eluate gave a solid which was crystallized from EtOAc–hexane; mp 70–85°. Repeated washes with cold Et₂O yielded 100 mg (4%) of a white solid, mp 108–110°. An analytical sample was recrystallized from EtOAc–hexane and dried over P₂O₅ *in vacuo*; mp 114–116°, tlc, one spot (EtOAc), R_f 0.58. *Anal.* (C₂₇H₃₇NO₄S₂) C, H, S.

N-Acetyl-3,5-di(ethylthio)-4-(4'-methoxyphenoxy)phenyl-L-alanine Ethyl Ester (5a).—A mixture of N-acetyl-3,5-diiodo-4-(4'-methoxyphenoxy)phenyl-L-alanine ethyl ester¹⁴ (**4a**, 3.8 g, 6 mmoles), cuprous ethyl mercaptide^{16b} (4.0 g, 32 mmoles), quinoline (10 ml), and pyridine (0.5 ml) was stirred and heated for 3.5 hr at an oil bath temperature of 175–178°, then poured into concentrated HCl (40 ml) and ice (300 g). After standing for 8 hr, the precipitated solid was removed by filtration, then extracted with CHCl₃ (800 ml). The CHCl₃ extract was washed with 5% HCl (800 ml) and H₂O (500 ml), dried (Na₂SO₄), and evaporated *in vacuo*. The residual black oil was chromatographed on acid-washed alumina (70 g). Four 250-ml fractions were collected: C₆H₆, 20% CHCl₃ in C₆H₆, 50% CHCl₃ in C₆H₆, and CHCl₃. The residue from evaporation of the 50% CHCl₃ in C₆H₆ was chromatographed on silicic acid (35 g). After 200 ml of C₆H₆, 50% CHCl₃ in C₆H₆ was the eluting solvent. Evaporation yielded a brown solid which was recrystallized from EtOAc–hexane (Norit) to give 60 mg (2%) of **5a**: mp 107–108°; iodine absent; tlc, one spot, R_f 0.71 (EtOAc). *Anal.* (C₂₄H₃₁NO₄S₂) C, H, S.

N-Acetyl-3,5-di(phenylthio)-4-(3'-isopropyl-4'-methoxyphenoxy)phenyl-L-alanine Ethyl Ester (8b).—A stirred mixture of **4b** (3.2 g, 4.9 mmoles), cuprous ethyl mercaptide^{16a} (4.5 g, 26 mmoles), quinoline (8.2 ml), and pyridine (0.4 ml), through which N₂ was passed, was heated at a bath temperature of 168–170° for 3.5 hr. The reaction mixture was poured onto a mixture of ice (300 g) and HCl (40 ml) and allowed to stand overnight. The precipitated solid was removed by filtration, extracted with Et₂O (1 l.), H₂O (1.5 l.), 10% NaHSO₃ (100 ml), and H₂O (200 ml), and dried (Na₂SO₄). The ether was removed by distillation, leaving a dark oil (3.4 g) which solidified on standing; colorless crystals from Et₂O, 1.21 g (40%), mp 94–99°. An analytical sample was recrystallized from Et₂O; mp 97–99°, iodine absent. *Anal.* (C₃₅H₃₇NO₄S₂) C, H, S; calcd, 10.41; found, 9.89.

The same reaction carried out in the absence of N₂ resulted in a significantly lower yield.

N-Acetyl-3,5-di(phenylthio)-4-(4'-methoxyphenoxy)phenyl-L-alanine Ethyl Ester (8a).—A mixture of **4a** (3.8 g, 6 mmoles), cuprous ethyl mercaptide^{16a} (5.3 g, 32 mmoles), quinoline (10 ml), and pyridine (0.5 ml) was heated at a bath temperature of 175–183° for 3.5 hr without N₂ cover. The reaction mixture was treated as was **8b**, to yield 4.6 g of a dark oil which solidified on standing. Crystallization (EtOAc–heptane) followed by washes with cold Et₂O gave 130 mg (4%) as colorless crystals, mp 115–117°, iodine absent. *Anal.* (C₃₂H₃₁NO₄S₂·0.5H₂O) C, H, S.

3,5-Di(phenylthio)-4-(4'-hydroxyphenoxy)phenyl-L-alanine (9a).—N₂ was passed through a solution of **8a** (267 mg, 0.45 mmole) in 4.3 ml of HOAc for 30 min. HBr (48%, 1.1 ml) was added and the solution was heated under N₂ and refluxed for 3.5 hr. A white precipitate formed on addition of H₂O. The solvents were removed *in vacuo*, the residue was dissolved in 5% NaOH (70 ml) and filtered, and the pH was adjusted to 5.0 with 4 N HCl giving 172 mg (77%) of a white solid, mp 225–245° dec. Two more isoelectric precipitations gave 132 mg (60%) of a white solid: mp 232–236° dec; tlc (BAW), one spot, ninhydrin positive, Pauly positive. *Anal.* (C₂₇H₂₉NO₄S₂) C, H, S; calcd, 13.10; found, 12.49.

3,5-Di(phenylthio)-4-(3'-isopropyl-4'-hydroxyphenoxy)phenyl-L-alanine (9b).—The N-acetyl ester (**8b**) (130 mg, 0.21 mmole) was heated under reflux (N₂) in HOAc (2.2 ml) and 48% HBr (0.6 ml) for 3.5 hr. Work-up as described for **9a** gave 68 mg (61%); mp 154–159° dec; tlc (BAW), one spot, ninhydrin positive, Pauly positive. *Anal.* (C₃₀H₃₃NO₄S₂·0.5H₂O) C, H, S.

Attempted Formation of 3,5-Di(ethylthio)-4-(3'-isopropyl-4'-hydroxyphenoxy)phenyl-L-alanine (6b).—The N-acetyl ethyl ester (**5b**) (100 mg) in 2 ml of HOAc and 0.5 ml of 40% HBr was heated under reflux for 4 hr (N₂). Additional HOAc (1 ml) and HBr (0.3 ml) were added at 1, 2, and 3 hr. Work-up as described for **9a** gave 64 mg, mp 132–220°. Nmr and ir showed absence of OCH₃, amide, and ester groups, and a partial loss of SC₂H₅; tlc (BAW), two spots, ninhydrin positive, Pauly positive. The mixture was used in biological testing. *Anal.* Calcd for C₂₂H₂₉NO₄S₂: C, 60.66; H, 6.71; N, 3.21; S, 14.72. Found: C, 57.09; H, 5.95; N, 3.20; S, 10.33.

3,5-Di(ethylthio)-4-(4'-hydroxyphenoxy)phenyl-L-alanine (6a).—The N-acetyl ethyl ester **5a** (200 mg) in 4 ml of HOAc and 1 ml of 48% HBr was heated under reflux for 3 hr. The solvents were removed *in vacuo*, and the residue was dissolved in 5% NaOH and precipitated at pH 5.0 by addition of dilute HCl. The precipitate was filtered, dissolved in dilute HCl, and precipitated at pH 5.0 with 5% NaOH, giving 125 mg (72%); mp 205° dec; tlc (BAW), one spot, ninhydrin positive, Pauly positive; λ_{max} (0.05 N NaOH) 301 mμ (ε 4120), λ_{max} (dilute HCl) 284 mμ (ε 3940). *Anal.* (C₁₉H₂₅NO₄S₂) H, S; C: calcd, 55.45; found, 56.04.

3,5-Di(ethylthio)-4-(3'-isopropyl-4'-methoxyphenoxy)phenyl-L-alanine (7).—The N-acetyl ethyl ester (**5b**) (100 mg) in 3.6 ml of HOAc and 2.4 ml of HCl was heated under reflux for 3.5 hr (N₂). Additional 1-ml portions of HCl and HOAc were added at 1 hr and 2.5 hr. Addition of 2 N NaOH to pH 5.0 gave a precipitate which was collected, dissolved in HOAc–HCl, and reprecipitated at pH 5.0 with 2 N NaOH to give 32 mg (36%) of a white solid: mp 175–180° dec; tlc (BAW), one spot, ninhydrin positive, Pauly negative. *Anal.* (C₂₃H₃₁NO₄S₂·H₂O) C; H: calcd, 7.11; found, 6.46; S: calcd, 13.71; found, 12.96.

(23) E. C. Jorgensen and J. A. W. Reid, *J. Med. Chem.*, **8**, 533 (1965).